India Proposes New Production Linked Incentive Scheme For Nutraceuticals

The Bottom Line

•The government is planning a PLI scheme to boost domestic production of health supplements and reduce import dependency.
•Expect new manufacturing investment announcements as companies prepare to capitalize on the upcoming sectoral incentives.

[Sectoral Policy Boost]:

The Ministry of Food Processing Industries has initiated industry consultations to draft a new Production Linked Incentive (PLI) scheme for the nutraceuticals sector. This policy aims to position India as a global manufacturing hub for health supplements and functional foods. By providing financial sops and subsidies, the government intends to reduce reliance on imported raw materials and scale up domestic production, mirroring the success of previous PLI schemes implemented in the electronics and pharmaceutical industries since 2020.

[Regulatory Collaboration]:

The initiative involves inter-ministerial coordination between the Health Ministry, the Food Safety and Standards Authority of India (FSSAI), and the Drugs Controller General of India (DCGI). This collaboration is critical to resolving historical regulatory ambiguities where products often straddled the line between food and pharmaceuticals. Officials are working to create a streamlined framework that defines product classification and ensures high safety standards. Consultations with industry leaders are currently focused on identifying supply chain bottlenecks, such as high raw material costs and the need for advanced domestic testing laboratories.

[Economic Growth Prospects]:

India’s nutraceutical market is currently experiencing a rapid growth trajectory, driven by rising health consciousness among the urban population. With government support, the sector is expected to increase its footprint in global markets, particularly in North America and Europe. The expected financial outlay, to be finalized by the end of the fiscal year, is anticipated to attract significant foreign direct investment and create thousands of specialized jobs in bio-tech and agro-processing. Analysts suggest this policy will significantly enhance the wellness portfolios of major domestic companies.

Pulse Intelligence

^{Context & Impact}

Context & Background

The Indian nutraceutical sector has seen rapid growth but remains fragmented due to varying regulatory definitions and import dependency.
The PLI framework, introduced in 2020 under the 'Atmanirbhar Bharat' initiative, has served as the successful blueprint for this sectoral intervention.
India possesses significant natural resources in traditional herbal and medicinal ingredients that are currently underutilized in large-scale supplement manufacturing.

Key Consequences

Domestic manufacturing of vitamins and specialized health supplements is expected to rise, significantly reducing import costs for manufacturers.
Leading domestic food and pharmaceutical firms will likely announce large-scale investment plans to qualify for the incoming manufacturing sops.
Consumers can expect a wider range of high-quality, locally manufactured health products at more competitive price points.

Market & Economic Impact

Positive for Nifty Pharma and FMCG companies such as ITC, HUL, and Sun Pharma as they expand their wellness portfolios.

The Indus Pulse is committed to accuracy and transparency.

Report a Correction Editorial Standards